{
    "Trade/Device Name(s)": [
        "Revogene",
        "Revogene instrument"
    ],
    "Submitter Information": "Meridian Bioscience, Inc.",
    "510(k) Number": "K222779",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220480"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OOI"
    ],
    "Summary Letter Date": "January 26, 2023",
    "Summary Letter Received Date": "September 14, 2022",
    "Submission Date": "September 14, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Instrumentation for clinical multiplex systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "misc"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Various clinical specimen types"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Revogene instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Automated lysis",
        "Automated dilution",
        "Fluorescence-based real-time PCR",
        "Automated amplification",
        "Automated detection of nucleic acid sequences"
    ],
    "Methodologies": [
        "Real-time PCR",
        "Nucleic acid testing"
    ],
    "Submission Type(s)": [
        "Instrument",
        "Platform"
    ],
    "Document Summary": "FDA 510(k) summary for Meridian Bioscience Revogene instrument firmware modification to add cooling sequence before lid opening in interrupted runs",
    "Indications for Use Summary": "Intended for in vitro diagnostic use in clinical laboratories to perform nucleic acid testing of specific IVD assays via automated lysis, dilution, amplification, and fluorescence-based real-time PCR detection of target nucleic acid sequences",
    "fda_folder": "Clinical Chemistry"
}